<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687071</url>
  </required_header>
  <id_info>
    <org_study_id>346-102-00003</org_study_id>
    <nct_id>NCT05687071</nct_id>
  </id_info>
  <brief_title>A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia</brief_title>
  <official_title>A Multicenter, Open-label, Uncontrolled, Long-term Trial to Assess the Safety and Efficacy of ETC-1002 in Patients With Hyper-LDL Cholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg&#xD;
      administered for 52 weeks in patients with hyper-LDL cholesterolemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2023</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From baseline to week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to Week 52</measure>
    <time_frame>Baseline, week52</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hyper-low-density Lipoprotein (LDL) Cholesterolemia</condition>
  <arm_group>
    <arm_group_label>ETC-1002 180mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180mg of ETC-1002(bempedoic acid)</intervention_name>
    <description>180mg, tablet, once daily, for 52 weeks</description>
    <arm_group_label>ETC-1002 180mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with inadequate response to statins or who have difficulty in treatment with&#xD;
             statins as defined below [Inadequate response to statins] Patients with hyper-LDL&#xD;
             cholesterolemia who are currently taking or have previously taken statins[and other&#xD;
             lipid-modifying therapies(LMTs) if needed] and cannot achieve the lipid management&#xD;
             goals of LDL-C [Difficulty in treatment with statins] Patients with hyper-LDL&#xD;
             cholesterolemia for whom safety problems have occurred while taking at least one type&#xD;
             of statin, and who experienced resolution of the problems after discontinuation or&#xD;
             dose reduction, or of those patients who have a history of statin administration and&#xD;
             who are judged to have concerns of safety problems associated with the administration&#xD;
             or dose increase of statins and who cannot achieve the lipid management goals of&#xD;
             LDL-C. Patients must be on the lowest or under the dosage of the approved dose of&#xD;
             statin and/or on stable LMT(s).&#xD;
&#xD;
          -  Patients with fasting TG levels of &lt;400 mg/dL at screening&#xD;
&#xD;
          -  Other protocol specific inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding or who have a positive pregnancy test&#xD;
             (urine) result at screening or baseline visits&#xD;
&#xD;
          -  Patients with homozygous familial hypercholesterolemia (HoFH)&#xD;
&#xD;
          -  Patients who currently have or who have had within the past 3 months prior to&#xD;
             screening any cardiovascular diseases, or those who have developed any cardiovascular&#xD;
             diseases during the screening&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5&#xD;
             minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening&#xD;
&#xD;
          -  Patients with uncontrolled and serious hematologic or coagulation disorders or with&#xD;
             hemoglobin of &lt;10.0 g/dL at screening&#xD;
&#xD;
          -  Patients with uncontrolled diabetes with HbA1c of ≥9% at screening&#xD;
&#xD;
          -  Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of&#xD;
             &gt;1.5 × ULN at screening&#xD;
&#xD;
          -  Patients with liver disease or dysfunction, including:&#xD;
&#xD;
               -  Positive serology for hepatitis B surface antigen (HBsAg) or a positive hepatitis&#xD;
                  C virus (HCV) antibody test at screening&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or&#xD;
                  total bilirubin of ≥2 × ULN at screening&#xD;
&#xD;
          -  Patients with creatine kinase (CK) of &gt;3 × ULN at screening&#xD;
&#xD;
          -  Patients with a history or current renal dysfunction, nephritic syndrome, or&#xD;
             nephritis, and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2&#xD;
             at screening&#xD;
&#xD;
          -  Other protocol specific exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 4, 2023</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

